title: Can We Predict Bevacizumab Responders in Patients With Glioblastoma?
authors.affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ mayertm@cinj.rutgers.edu.
authors.forename: Tina M
authors.initials: TM
authors.lastname: Mayer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003606:Dacarbazine / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine